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Immunoaffinity Cl-~romatography
Anuradha Subramanian

1. Introduction
Recent devclopments in recombinant DNA technology have enabled the
synthesis of valuable therapeutic proteins in bacterial cells as well as in novel
eucaryotic expression systems. However, the purification of proteins of interest from either the conventional sources, cell culture, or novel routes in a highly
purified form necessitates the development of separation tcchniques capable of
recovering proteins from these feed streams in a highly purified form (1,2).
Purification of therapeutic proteins from biological sources is usually complicated by the presence of endogenous proteins (2). Purification methodologies
based on ion exchange or adsorption serve as excellent prepurification steps,
but they fail to resolve complex protein mixtures to yield a homogeneous protein product (l).Purification techniques based on affinity interactions between
molecules (i.e., immunoaffinity chromatography, IAC) have rapidly evolved
using a variety of biological and synthetic ligands (2).
1. I . lmmunoaffinity Chromatography

Itnmunoaffinity chromatography is a process in which the binding affinity
of an antigen (Ag) to a parent antibody (Ab) is utilized as a basis of separation.
The antibody specific to the protein of interest is immobilized onto a rigid solid
support to yield an active immunosorbent. A complex mixture of proteins is
then passed over the immunosorbent whereby the antibody captures the protein of interest and the other nonproduct proteins are washed away in the column fall through (1,s). The reversible interaction between the antigen and
antibody can be disrupted to yield a highly purified product in the column eluate (2). This could be achieved by changes in pH or use of chaotropes such
sodium or potassium thiocyanateslureas as eluents. Due to the customized avidFrom: Methods in Molecular Biology, vol. 147: Affinity Chromatography: Methods and Protocols
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ity and specificity, n~onoclonalantibodies (mAbs) have become indispensable
for both protein characterization and purification (5).
Irn~nunoglobulin(IgG) is an approximately 150,000 Dalton molecular
weight glycoprotein. The association constant for the binding of antigens to
antibodies (free to bound) is about 10-~-10-'~
M. The symmetry of the Fab fragments on the antibody molecule predetermines a theoretical antigen binding stoichiometry of 2:1 (molar basis) (3). Pritnary amines (lysine residues) are found
throughout the antibody molecule, whereas carbohydrate (CHO) moieties are
mainly found in the Fc region. Most of the linker chemistries engineer covalent
attachment of the antibody via the primary amines or the C H 0 residues.
1.2. Support Characteristics

The ~~nmunosorbent
performance is dependent on the support matrix on
which the antibody is irnn~obilized.Efficient immunosorbents should possess
mechanical/physical stability, good flow properties, acceptable pressure drop,
nlinimal nonspecific binding, surface area for Ab-Ag interactions, and chemical stability (10).Polymeric andlor agarose based supports are extensively used
in affinity chromatography. Both of the aforementioned supports lend themselves to a variety of conjugation chemistries and offer reasonable physical1
mechanical properties and are resistant to the various solvent systems used in
affinity chromatography. The functioning of an immunosorbent column is
dependent on the activation chemistry used to couple the antibody to the matrix.
2. Materials
2.1. Chromatographic Columns

Use jacketed columns from Pharmacia Biotech. These glass columns come
in different sizes complete with flow adaptors, jackets, and fittings. Please read
the instructions accompanying these columns for proper assembly.
2.2. General Laboratory Equipment
1.
2.
3.
4.

Bench-top laboratory centrifuge (operating speed 500-1000 rpm)
End-to-end rotator
Polypropylene bottles (Nalgene)
Masterflex peristaltic pumps

2.3. Reagents

Activated matrices supporting different activation chemistries are c
available and can be purchased from appropriate vendors. Emphaze
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2.4. Apparatus
Assemble a chromatographic station required f o r running the I A C that
includes a peristaltic p u m p (Masterflex, Cole-Palmer), which supports flow rates
between 0.5-5 mLIinin, a flow-through UV-absorbance monitor (Bio-Rad or
Rainin), chart recorder, columns with flow adaptors, and a fraction collector.
Configure the system t o enable sequential delivery of the feed and buffers through
the pump, column, UV detector and fraction collector (see Fig. 1).

2.5. Antibody Sample Preparation
l . For a lyophilized antibody, dissolve the antibody in an antibody-coupling buffer.

Make sure that the lyophili~ationbuffer does not contain amines such as glycine
or Tris.
2. For an antibody in solution (samplcs in buffers, IgG fractions, and so forth):
Make sure that the antibody solution does not contain primary amines such as
Tris or glycine. Remove any primary amines present by dialysis 01gel filtration.

2.6. N-Hydroxysuccimide (NHS) Activation
1. NHS activated matrix (Note: Activated beads are supplied as a suspension in
ethanol as 5070 (v/v) solution).
2. Antibody-coupling buffer (0.1 M 4-mortholinepropanesulfonic acid (MOPS), 0.1 M
NaCI, pH 7.2).
3. Blocking buffer ( l M ethanolamine, pH 8.0).
4. Ligand-loading buffer (10 n M Tris-HC1, 50 mM NaCl, pH 6.8).
5. Distilled water (Keep cold at 4°C.).

1.
2.
3.
4.

Emphaze activated matrix.
Antibody-coupling buffer (0.05 M sodium phosphate, 0.75 M Na,S04, pH 7.0).
Blocking buffer ( l M ethanolamine in 0.05 M sodium pyrophosphate, pH 9.3).
Ligand-loading buffer ( l 0 mM Tris-HC1, 50 mM NaC1, pH 6.8).

3. Methods
3.1. Coupling Through Primary Amino (-NHd Groups

3.1. l. NHS Activation
1. Invert the bottles containing the activated matrix gently to obtain a well-mixed
slurry. Pour 500 n1L of well-mixed slurry on a sintered glass funnel and then suck
the liquid through by gentle vacuum suction. This amount of slurry will yield a
final sorbent volume of 250 mL. Stir the suspension with a glass rod to disperse
the gel and take care to keep the gel moist at all times.
2. Wash the activated resin with 1.5 L of ice cold distilled water.. Repeat the wash
step four to five times with distilled water to ensure the removal of ethanol. Drain
water using gentle vacuum and transfer the moist gel to a 2-L Erlenmeyer flask
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Sample

Fig. l . Chromatographic apparatus and setup.

3.

4.

5.

6.

containing 1000 mL of a 3-5 mg/mL of antibody solution in coupling buffer.
Carry out t h ~ sstep In the cold room. Place a medium-sized magnetic stlr In the
flask. Place the flask w ~ t hthe contents on a shaker and mix the contents on low
speed for 24 h in the cold room or for 4 h at room temperature. Avoid '1'g orous
shaking as that may lead to mechanical damage of the act~vatedmatrix (see Fig.
2 for antibody coupling reaction).
Allow the gel to settle after completion of the coupling step (i.e., step 2) at
room temperature (RT). Remove the supernatant by aspiration or decanting.
Use care to retain beads in bottle. This supernatant should be saved for the
determination of the amount of uncoupled antibody. The chemical compound
released upon the reaction of the activated ester and the reactive amine to
form a stable amide linkage interferes with AL80measurement and hence measuring AZ8" nm of the supernatant cannot be rellably used to estimate the
amount of the uncoupled antibody.
Add 2.5 L of blocking solution to the immunosorbent and mix the contents of the
flask on a shaker at low speed for 1 h at room temperature. Upon completion of
the blocking step, allow the gel to settle at RT and remove the supernatant by
aspiration or decanting. Use care to retain beads in bottle. To ensure complete
blocking of unused activated sites, repcat the blocking step two times as before.
The blocking-step supernatant should be saved for the determination of unbound
antibody.
Add 1000 mL of ligand-coupling buffer to the antibody-coupled beads and mix
the contents of the flask on a shaker at low speed for 1 h at room temperature.
Repeat step 5 four to five tlmes to ensure hat all of the blocking solution has
been removed. Suspend the immunosorbent in 500 mL of ligand-coupling buffer
after the final wash step and store at 4OC until further use.
Immunosorbent thus prepared is ready for use and can be packed in columns by gravity. In the event that the immunosorbent is being prepared for
future use, store the immunosorbent in Iigand-coupling buffer containing
0.02% sodium azide.
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Fig. 2. Antibody coupling to NHS-activated matrix.

EmphazeTMmatrix.

Antibody.

Stable immunosorbent.

Fig. 3. Antibody-coupling reaction to Emphaze.

3.1.2. EMPHAZE JM
1. Refer to the individual lot swell volume value to determine the quantity of beads

needed for the colun~n.Typically 70-100 mg of dry beads give 1 mI, of swelled
gel. Weigh out 25 g of dry Emphaze to yield a final sorbent volume of 250 mL
and transfer it to a l-L polypropylene bottle (.we Fig. 3 for antibody coupling
reaction). Take necessary precautions in handling dry sorbent.
2. Prepare 125 mL of an antibody solution at a concentration of 3-5 mg antibody
per milliliter of coupling buffer and add it directly to the weighed sorbent in the
bottle. Use antibody-coupling buffer to prepare the antibody solution. Tlzere is no
need to preswell the beuds prior to use; the coupling buffer will swell tlze bends.
Gently rock or rotate the bottle to keep the beads suspended and carry out the
coupling reaction for solution for 1 h at RT or for 24 h at 4°C. Avoid using
magnetic stir bars because their use may damage the beads.
3. Centrifuge the contents of the bottle at 1200g for 5-10 min in a bench-top laboratory centrifuge until beads are pelleted. Centrifugation may be done at RT.
Remove supernatant by aspiration or decanting. Use care to retain beads in bottle.
This supernatant may be used to determine of the amount of ligand not coupled to
the beads. Due to use of Triton X- 100 surfactant in production of the beads, there
may be interference with an A280nmmeasurement of the uncoupled protein.
4. Add 500 mL of blocking solution directly to the bottle to quench the unreacted
azlactone sites. Gently rock or rotate the bottle for 2.5 h. Centrifuge the contents
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of the bottle at 1200g for 5-10 min or until beads are sedimented. Repeat the
blocking step three times as outlined in step 4 to ensure complete ~nactivationof
unused azlactone sites. Remove and save supernatant after centrifugation to
determine ot unbound antibody. Decant the blocking solution at the end of the
blocking steps to yield a moist ~mmunosorbent.
5. Resuspend the immunosorbent in 500 mL of PBS. Rock or rotate sa~llpleto keep
beads suspended in wash solution. Centrifuge samples as in step 4. Repeat step 5
three to four times and decant the supernatant to yield a moist immunosorbent.
6 Resuspend the immunosorbent in 500 mL of 1.0 M NaCI. Use of a high-salt wash
solution, such as 1.0 M NaCI, will remove nonspecifically attached protein. Rock
or rotate sample to keep beads suspended in 1.0 M NaCl for 30 min. Centrifuge
samples as in step 4.
7. Resuspend immunosorbent in 500 mL of ligand-coupling buffer. lmmunosorbent
thus prepared is ready for use and can be packed in columns by gravity. In the
event that the immunosorbent is belng prepared for future use, store the
immunosorbent in ligand-coupling buffer containing 0.02% sodium azide.

3. Typical Protocol for lmmunoaffinity Chromatography
This is a typical protocol for the purification of antigen on an antibody column. Some antigens require more or less stringent conditions for dissociation
from an immobilized antibody and conditions for elution may have to be determined experimentally.

3.2.1. Preparation of the lmmunoaffinity Column for Use
1. Bring the prepared immunosorbent to room temperature.
2. Assemble a column with adapters. Pour the beads from the top with the help of a
funnel and when packed place the top adapter and connect the tubing (see Fig. 1).
A jacketed column from Pharmacia with an lnternal diameter of 5.0 cm is recommended
3 Equilibrate the column with 10 column volumes (CV)of antigen-loading buffer
such as 10 mM Tris-HCI buffer, 50 nlM NaCI, pH 7.0

3.2.2. Sample Application and Elution
1. Clarlfy and centrifuge the crude sample containing the antigen to be purified by
low-speed centrifugation and filtering through a 0.45- to 0 . 2 - p filter. Failure to
remove cell debris and particulate matter from the feed sample may lead to clogging and fouling of the immunosorbent. This may lead to shorter shelf hfe of th
column.
2. Dilute the crude sample containing the antigen to be purified to total prote
concentration 5 mg/mL with the antigen-loading buffer. Use OD280nm to me
sure the total protein concentration of the crude sample.
3. Load the sample to the packed immunosorbent at a flow rate of l mL/min. Operate the column between h e a r flow rates (U) of 0.75 to 1.5 crnlmin. For most
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chromatographic operations 14 is defined as the volumetric flow rate in mL/min
{Q]/cross-sectional area of the column in cm2 { A ] where A = 3.14 (R 2 );R is the
radius of the column in centimeters.
4. Wash with the antigen-binding buffer until baseline absorbance at 280 nm is
reached.

3.3. Selection of an Elution Strategy
Antigens and antibodies are bound to each other by a web of forces, which
include ionic bonding, hydrophobic interactions, hydrogen bonding, and van
der Waals attractions. The strength of Ag:Ab complexes depends o n the relative affinities and avidities of the antibodies. In addition, steric orientation,
coupling density, and nonspecific interactions can also influence the binding.
The objective of the elution step is to recover the specifically bound protein at
a high yield, purity, and stability. Elution conditions, which might denature the
re
protein product, have to be avoided. Examination of the current l i t e r a t ~ ~suggests a wide variety of elution conditions and the choice of an eluant seems
empirical. However, a logical sequence of available elution strategies can be
considered when selecting an appropriate elution protocol. T h e logical
sequence as follows:
1. Specific elution: Certain antibodies bind to their respective antigens under high
pH or in the presence of metals like calcium or magnesium or in the presence of
chelating agents like EDTA. Antigens bound to such antibodies can be eluted
under gentle conditions where lowering the pH or adding EDTA to the elution
buffer or adding divalent metals to the elution buffer causes the Ag:Ab complex
to disassociate.
2. Acid elution: This is the most widely used method of desorption and is normally
very effective. The commonly used acid eluants are glycine-HC1, pH 2.5,0.02 M
HCI and sodium citrate, pH 2.5. Upon elution, quickly neutralize the pH of the
eluant sample to 7.0 with 2 M Tris base, pH 8.5, to avoid acid-induced denaturation. In some cases increased hydrophobic interactions between antigen and antibody gives low recovery with acid elution. Incorporating of 1 M propionic acid, or
adding 10% dioxane or addition of ethylene glycol to the acid eluant, is effective in
disassociating such complexes.
3. Base elution: It is less frequently employed than acid elution. Typically, 1 M
NH,OH, or 0.05 M diethylamine, pH 11.5 have been employed to elute membrane proteins (i.e., hydrophobic character) and other antigens that precipitate in
acid but are stable in basic conditions.
4. Chaotropic agents: These agents disrupt the tertiary structure of proteins and,
therefore, can be used to disrupt the Ag:Ab complexes. Chaotropic salts are particularly useful as they disrupt ionic interactions, hydrogen bonding, and sometimes hydrophobic interactions. The relative order of the effectiveness of
chaotropic anions is SCN->C104->I->Br->Cl-. Chaotropic cations are effective
in the order of Gu>Mg>K>Na. Eluants such as 8 M urea, 6 M guanidine-HC1, and
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4 M NaSCN are effective in disrupting most Ag:Ab interactions. To avoid and
minimize chaotropic salt-induced protein denaturation, rapid desalting or dialysis of the eluant is advised.

3.4. Regeneration of the lmmunoaffinity Column
Wash with 3-4 CV of the 4 M NaCl or glycine-HCl buffer. Store at neutral
pH in water or buffer containing a preservative, 0.02% sodium azide.

4. Notes
1. Before beginning antibody immobilization on commercially available matrices,
a decision regarding the final immobilized antibody density has to be made. It is
advisable to aim for immobilized antibody densities between 3-5 mg of antibody
per milliliter of gel. Immobilizations at high densities > 8 mgImL yield reduced
antibody utilization due to steric hindrance and overcrowding effects.
2. It is recommended that a coupling chemistry based on the scale and the strin- ,
gency of the purification is selected. We have routinely purchased commercially
available activated matrices and provided the coupling instructions are followed.
little or no problems were encountered.
3. It is recommended that antibody-coupling efficiency to the support matrix be
evaluated. Antibody-coupling efficiencies in the range of 75-95% are acceptable. If coupling efficiencies less than 70% are attained, check the antibody-coupling buffers and the antibody samples for the presence of salts like Tris-HC1 or
glycine. Dialyze the antibody samples extensively to ensure the removal of salts
like Tris and glycine. Alternatively, choosing another in~mobilizationchemistry
may give higher antibody-coupling efficiencies.
4. The amount of antibody immobilized on the support matrix is calculated as the
difference between total antibody added to the gel and the uncoupled antibody
recovered in the blocking step supernatants and wash pools, as measured by A2*@
The antibody-coupling efficiency was calculated as the ratio of [coupled Ab:total
Ab]. 100%. However certain activation chemistries (NHS or Emphaze) release
substances as a result of the coupling reaction that may interfere with measurements at A280 The following protocol may be used to estimate the coupling efficiency when immobilizing monoclonal antibodies (mAb). Coat Immulon I1
96-well microtiter plates with 100 Wlwell of 1:200 diluted anti-mouse whole
molecule in 0.1 M NaHCO, (pH 9.3) for 24 h at 4°C. Wash and aspirate the wells
with 0.05 M TrisIO.l M NaCl/O.O5% Tween (TBS-Tween) and block the residual
reactive sites with TBS/O.l% BSA for 20 min at RT. Add various dilutions of
standard and samples in TBS/O.l% BSA to the wells, 100 JJLin each well and
incubated for 20 min at 37°C. The concentration of the MAb standard in the
assay ranges from 50 ng/mL to 0.78 ngImL. Upon incubation, wash the wells
four times. Add 1:1000 diluted horseradish peroxidase (HRP) conjugated goat
antimouse IgG to the wells and incubate for 20 min at 37'C. Wash and aspirate
the wells four times and add 100 pL of OPD substrate to each well. Stop the
colorimetric reaction after 3 min by the addition of 100 mL of 3 N H2S04to each
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well. Bound chromophore can be detected at 490 nm using an EL308 Bio-Tek
Microplate reader.
5. The theoretical antigen binding efficiency (vAg)of immobilized monoclonal antibody (mAb) assuming a 2: 1 antigen to antibody stoichiometry can be calculated
as follows:
M = Immobilized MAb density, mg antibodylml of gel
MW(,Ab, = molecular weight of MAb, 150,000 Daltons
MW(,,, = molecular weight of antigen being purified, in Daltons
V = volume of gel, mL

Theoretical maximum
antigen binding =

[W X [WX (MW,,,,IMW~MA,~)X (2111 X 100

(1)

Eq. 1 predicts the theoretical maximum antigen-binding capacity. The amount
of antigen present in the eluate peaks can be measured by specific antigen assays
and
measurement. Based on the amount of antigen eluted as determined by
protein assays, the antigen-binding efficiency can be calculated as follows:
[qAg]= [total amount of eluted antigenltheoretical maximum antigen binding]

X

100

6. It is advisable to calculate the efficiency of the immobilized mAb for the antigen-antibody system being employed. If the antigen-binding efficiency is too
low, selecting another coupling chemistry may prove beneficial. However, using
current immobilization techniques, antigen-binding efficiencies in the range of
10-30% have been obtained. Selection of site-directed chemistries may offer
better performance.
7 . Also, check for antibody leakage in all column washes and eluants. Traditionally, CNBr-activated supports have shown to leach some percentage of anchored
antibody due to the hydrolysis of the isourea linkage. Affi-prep and Emphaze
show reduced or minimal antibody leaching.
8. Immobilization procedures outlined in this chapter are applicable to both polyclonal
and monoclonal antibodies. Antigen-binding efficiencies in the range of 8-15% can
be expected of polyclonal antibodies using procedures outlined in this chapter.
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